InMed Pharmaceuticals (INM) Change in Accured Expenses (2019 - 2026)
InMed Pharmaceuticals (INM) posted Change in Accured Expenses of $113837.0 for Q1 2026, up 295.1% on a QoQ basis from -$58348.0 in Q4 2025, and up 270.87% year-over-year from $30694.4 in Q1 2025.
Powered by 
Analysis
InMed Pharmaceuticals (INM) Change in Accured Expenses (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals has reported Change in Accured Expenses for 8 years, with the latest figure at $113837.0 in Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 270.87% year-over-year to $113837.0 in Q1 2026; TTM through Mar 2026 was -$118906.0, a 198.0% decrease from a year earlier, with the FY2025 full-year figure at -$249728.0, down 651.5% from the prior year.
- Change in Accured Expenses was $113837.0 for Q1 2026 at InMed Pharmaceuticals, up from -$58348.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $470728.0 in Q2 2024, with the low at -$642392.0 in Q3 2024.
- Average Change in Accured Expenses over 5 years is -$137505.2, with a median of -$104340.0 recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses slumped 253.19% in 2023, then soared 312.82% in 2024.
- Over 5 years, Change in Accured Expenses stood at -$349611.0 in 2022, then soared by 169.04% to $241378.0 in 2023, then soared by 48.98% to $359614.0 in 2024, then slumped by 116.23% to -$58348.0 in 2025, then jumped by 295.1% to $113837.0 in 2026.
- The last three Change in Accured Expenses figures came in at $113837.0 (Q1 2026), -$58348.0 (Q4 2025), and -$274066.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Corning | 145.18 Bn | 142.67 Bn | 1.63 Bn | 275.00 Mn |
| 2 | Ati | 28.28 Bn | 27.50 Bn | 309.80 Mn | - |
| 3 | Qnity Electronics | 26.28 Bn | 25.32 Bn | 666.00 Mn | 110.00 Mn |
| 4 | International Flavors & Fragrances | 21.50 Bn | 20.93 Bn | 853.00 Mn | 77.00 Mn |
| 5 | DuPont de Nemours | 17.40 Bn | 15.66 Bn | 639.00 Mn | - |
| 6 | Avery Dennison | 12.97 Bn | 12.74 Bn | 729.40 Mn | - |
| 7 | Solstice Advanced Materials | 10.03 Bn | 9.28 Bn | 370.00 Mn | 12.00 Mn |
| 8 | Element Solutions | 8.73 Bn | 8.54 Bn | 334.00 Mn | 5.50 Mn |
| 9 | Eastman Chemical | 7.82 Bn | 7.13 Bn | 560.00 Mn | - |
| 10 | InMed Pharmaceuticals | 5.30 Mn | 61,528.56 | - | 113,837.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 113,837.00 |
| Dec 31, 2025 | -58,348.00 |
| Sep 30, 2025 | -274,066.00 |
| Jun 30, 2025 | 99,671.00 |
| Mar 31, 2025 | -66,621.00 |
| Dec 31, 2024 | 359,614.00 |
| Sep 30, 2024 | -642,392.00 |
| Jun 30, 2024 | 470,728.00 |
| Mar 31, 2024 | -104,340.00 |
| Dec 31, 2023 | 241,378.00 |
| Sep 30, 2023 | -562,484.00 |
| Jun 30, 2023 | -221,189.00 |
| Mar 31, 2023 | -76,470.00 |
| Dec 31, 2022 | -349,611.00 |
| Sep 30, 2022 | -159,260.00 |
| Jun 30, 2022 | -616,474.00 |
| Mar 31, 2022 | -491,562.00 |
| Dec 31, 2021 | 765,664.00 |
| Sep 30, 2021 | -469,227.00 |
| Jun 30, 2021 | 582,577.00 |